Swissmedic swissdamed Importer Linking: April 1, 2027 Deadline for Medical Device Importers
Medical Device Global Market AccessSummary
Swissmedic, the Swiss Agency for Therapeutic Products, has implemented a new regulatory requirement that significantly affects medical device importers in Switzerland. As of October 1, 2026, importers must electronically link their Swiss single registration number, known as CHRN, to each medical device they import into the Swiss market. This requirement establishes a traceable connection in the Swiss Dam database between importers and the devices they handle, marking a critical shift in compliance responsibilities.
The successful implementation of this linking function relies on collaboration across the supply chain. Importers can only link to devices that have been registered in the Swiss Dam database, a task that falls to manufacturers or their designated Swiss authorized representatives. Consequently, effective communication between importers and manufacturers is essential to ensure that devices are registered in a timely manner, as any delays could jeopardize compliance.
Importers have until April 1, 2027, to complete the linking process for all devices they market. After this date, any device lacking the required link will be deemed non-compliant, potentially leading to market surveillance actions. To prepare, importers should verify their registration status in Swiss Dam, compile a list of devices with their corresponding UDI-DI numbers, and establish proactive communication with manufacturers regarding device registrations. This regulatory change underscores the necessity for a transparent and digitally connected supply chain in Switzerland.
Show Notes
Swissmedic has activated the importer linking function in the swissdamed database as of October 1, 2026. This creates a new mandatory step for Swiss importers, who now have until April 1, 2027, to electronically link their actor registration (CHRN) to the devices they place on the market. This episode breaks down the new obligation, explains its dependency on prior device registration by manufacturers and Swiss Authorized Representatives (CH-REPs), and outlines practical steps for all economic operators to ensure compliance before the deadline.
Key Questions: - What is the new importer linking function in Swissmedic's swissdamed database? - When did this new requirement become active? - What is the final deadline for Swiss importers to link devices? - Why is collaboration with manufacturers and CH-REPs essential for compliance? - What happens if a device is not registered by the manufacturer in swissdamed? - How does this linking process affect the responsibilities of a Swiss importer? - What practical steps should importers take now to prepare for the April 1, 2027 deadline? - How does the UDI-DI play a role in this new process? - What are the consequences of failing to link devices by the deadline?
Sources: - https://www.swissmedic.ch/swissmedic/en/home/medical-devices/market-surveillance/importers.html - https://www.medenvoy.com/resources/news/swissmedic-activates-swissdamed-importer-linking - https://www.pure-global.com/insights/swissdamed-importer-links-by-1-april-2027/ - https://www.simone-ronco.com/en/blog/swissdamed-importers-linking-devices - https://www.europe-it.com/blog/swissdamed-linking-of-udis/
How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts offer services like regulatory strategy, technical dossier preparation, and local representation in over 30 countries, including Switzerland. We can guide you through Swissmedic requirements, manage your swissdamed registrations, and ensure your quality systems are compliant. By combining local expertise with advanced AI, we streamline the entire process, from initial registration to post-market surveillance. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.
More from Medical Device Global Market Access
On October 6, 2026, the European Commission selected the first group of high-risk medical devices to undergo a Joint Clinical Assessment (JCA) under the new EU Health Technology Assessment Regulation (HTAR). This episode explains what this pivotal moment means for medical device manufacturers, which device categories are impacted, and how the JCA will reshape the pathway for pricing, reimbursement, and market access across the European Union. We discuss the heightened evidence requirements and provide practical steps for regulatory and market access teams to prepare for this new centralized assessment system.
Australia's Therapeutic Goods Administration (TGA) has updated its guidance on fee reductions for medical device conformity and ARTG application audits. Effective October 1, 2026, these changes introduce a new fee model for design examinations based on Unique Product Identifier (UPI) components, increase certain recertification fees, and raise the minimum fee for subsequent devices in mandatory audits. This episode details what these changes mean for manufacturers and how to prepare your regulatory strategy and budget.
Australia's Therapeutic Goods Administration (TGA) has clarified that many AI-powered digital scribes are considered medical devices, not simple administrative tools. Following a review published on October 16, 2023, the TGA found that 8 of 12 reviewed products were likely unapproved medical devices. This episode breaks down the TGA's reasoning, focusing on how a software's intended purpose—such as summarizing or analyzing clinical information—triggers regulatory oversight. We discuss the immediate compliance obligations for manufacturers and provide practical steps for developers of Software as a Medical Device (SaMD) to navigate this evolving regulatory landscape.
On October 14, 2026, Japan's PMDA published its draft guidance, 'Review Points for Medical Devices Utilizing Generative AI.' This episode explores the key safety and performance evaluation criteria that manufacturers must understand to successfully bring advanced AI-enabled medical devices to the Japanese market. We cover the PMDA's expectations for data quality, AI model lifecycle management, transparency, and risk management, providing practical steps for regulatory and quality teams to prepare for these new requirements.
Health Canada has released revised guidance on its framework for exceptional importation and sale of medical devices, effective October 16, 2026. This episode details the key clarifications for manufacturers facing potential device shortages, outlines the updated application requirements and responsibilities for importers, and highlights the upcoming stakeholder information session on October 21, 2026. We provide practical steps for regulatory and quality teams to adapt to these changes and leverage the framework as part of a robust supply chain strategy.